NCT03276052View on ClinicalTrials.gov

A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

November 26, 2021

Study Completion Date

November 26, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

Aclidinium Bromide 400 μg

Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)

Trial Locations (1)

610000

Research Site, Chengdu

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY